Stueland Katherine 4

What Happened Katherine Stueland, CEO of GeneDx Holdings Corp. (WGS), had 6,546 restricted stock units (RSUs) settle on March 9, 2026 (acquired at $0). To satisfy tax withholding on that vesting, 3,678 shares were sold in open-market transactions at a weighted average price of $86.75 for total proceeds of $319,059. The filing also reports the settlement/disposition of the 6,546 RSU-derived shares (reported as derivative activity).

Key Details

• Transaction date: March 9, 2026; Form 4 filed March 11, 2026 (reporting period 3/9/2026).
• Sale: 3,678 shares sold (weighted avg price $86.75); price range $86.5585–$86.75 per footnote. Proceeds ≈ $319,059.
• RSU settlement: 6,546 RSUs settled/treated as acquired at $0 (then disposition reported).
• Reason: Sale was a "sell-to-cover" to satisfy tax withholding obligations (not a discretionary sale by the reporting person).
• Post-transaction holdings: 44,955 shares of Class A common stock beneficially owned, plus RSUs representing up to 445,366 shares and options for 107,610 shares (subject to vesting).
• Vesting note: These RSUs vest 6.25% quarterly (first tranche vested March 9, 2023); RSUs do not have an expiration date per footnote.

Context This was a routine sell-to-cover following RSU settlement rather than an independent open-market sale motivated by trading decisions. The key items for investors are the small net sale (~3,678 shares) and the substantial remaining contingent exposure from unvested RSUs and options.